The Role of Lipopolysaccharide-Induced Cell Signalling in Chronic Inflammation.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing mechanistic concepts without primary data or systematic search methodology.
PubMed 35155966 · doi:10.1177/24705470221076390
What was done
This narrative review synthesized existing literature on the mechanisms of lipopolysaccharide (LPS)-induced cell signaling, immune dysregulation, and procoagulant effects, evaluating its pathological role in chronic conditions compared to severe sepsis.
What was found
The abstract reports no quantitative data or numerical findings. It conceptually describes that sub-septic, low-grade endotoxaemia and LPS-driven pathways contribute to the pathophysiology and progression of chronic disorders, specifically highlighting metabolic, cardiovascular, and neurodegenerative diseases.
Why it matters
It broadens the clinical relevance of LPS beyond acute sepsis, framing LPS-induced signaling as a shared mechanistic driver and potential therapeutic target across diverse chronic inflammatory illnesses.
Limits
The abstract provides no empirical data, statistical measures, or systematic review methodology. Specific patient populations, effect sizes, diagnostic thresholds for low-grade endotoxaemia, and interventional clinical trial outcomes are not reported.
Cited by
- supports LPS is the outer covering of gram-negative bacteria that reside in the gut and is an initiator of inflammation.